10x Genomics (TXG) EV to EBITDA (2019 - 2026)

10x Genomics has disclosed EV to EBITDA across 8 years of filings, most recently posting 227.2 for Q2 2026.

• In Q2 2026, EV to EBITDA fell 788.76% year-over-year to 227.2; the TTM figure through Jun 2026 stood at 50.27 (down 408.5% YoY), while the FY2025 annual figure was 25.57, down 265.04% from the prior year.
• EV to EBITDA came in at 227.2 for Q2 2026 at 10x Genomics, down from 128.98 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 32.99 in Q2 2025 to a low of 227.2 in Q2 2026.
• Average EV to EBITDA over 5 years is 84.66, with a median of 71.95 recorded in 2022.
• Year-over-year, EV to EBITDA jumped 170.13% in 2025 and sank 788.76% in 2026.
• Over 5 years, EV to EBITDA stood at 163.13 in 2022, then soared by 30.29% to 113.72 in 2023, then soared by 75.96% to 27.34 in 2024, then plunged by 191.83% to 79.79 in 2025, then sank by 184.74% to 227.2 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 227.2 in Q2 2026, 128.98 in Q1 2026, and 79.79 in Q4 2025.